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Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
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SUMMARY
Multiple myeloma is a clonal B-cell malignancy,
characterised by proliferation of plasma cells and
secretion of paraproteins. These plasma cells accumulate
predominantly in the bone marrow; rarely, they invade
other areas, especially the thorax. Myeloma presenting
with a pleural effusion is rare and reported in only 6%
of patients with myeloma. Such patients generally
present late and have a poor prognosis. Here, we
describe a patient presenting with a lung mass, renal
failure and a massive unilateral pleural effusion due to
multiple myeloma who was treated successfully.
BACKGROUND
Multiple myeloma (MM) is a haematological malignancy of, predominantly, the elderly. It is characterised by proliferation of malignant plasma cells
and subsequent overproduction of monoclonal
protein/immunoglobulins (M protein). The malignant cells primarily proliferate in the bone marrow.
Rarely, they also invade other structures, particularly the chest.
Pleural effusions are rare in MM and are reported in about 6% of patients with myeloma.1
The aetiology of such effusions is diverse. Broadly,
these can be categorised into non-myelomatous and
myelomatous pleural effusions (MPE). Common
causes of non-myelomatous effusions in MM
include infections, pulmonary embolism, congestive
heart failure, nephrotic syndrome, secondary neoplasms and amyloidosis. In <1% of cases,2 the effusions are a direct result of MM, termed as MPE.
Here, we report an MPE of IgG subtype. The
patient presented with massive pleural effusion and
lung mass, along with renal failure, was diagnosed
with MM and MPE and was started on treatment with
complete resolution of pleural effusion and signiﬁcant
improvement in renal function and lung mass.

right anterolateral chest wall. There were decreased
breathing sounds on the right side of the chest,
with dullness to percussion. Jugular venous distension and pedal oedema were not detected.
Cardiovascular, abdominal and neurological examinations were unremarkable.There was no cervical,
axillary or inguinal lymphadenopathy.

INVESTIGATIONS
Chest X-ray revealed complete opaciﬁcation of the
right hemithorax with contralateral mediastinal
shift suggestive of massive pleural effusion (ﬁgure 1).
Complete blood count showed haemoglobin of
9.9 g/dL, haematocrit of 31.5%, white cell count of
10.5×109/L with 63% neutrophils, blood urea nitrogen of 86 mg/dL, serum creatinine of 4.4 mg/dL and
serum calcium (Ca) of 7.8 mg/dL. Thoracentesis
revealed haemorrhagic, exudative effusion that was
lymphocytic predominant (pleural ﬂuid lactate
dehydrogenase was 4812 IU/L, pleural ﬂuid total
leucocyte count was 6912/mm3 with 35% neutrophils and 65% lymphocytes, pleural ﬂuid protein
was 8.5 g/dL and pleural ﬂuid glucose was 37 mg/
dL). Pleural acid fast bacilli smear and culture and
Genexpert/MTB were negative.
CT scan of the chest without contrast (ﬁgure 2)
revealed a right-sided mass causing erosion of the
adjacent fourth rib. Pleural ﬂuid cytology showed
atypical plasma cells consistent with MM. Biopsy
of the lung mass, performed to rule out a concomitant secondary malignancy, demonstrated sheets of
plasmacytoid cells that stained positive for Mum-1,
CD138 and CD56, features suggestive of a
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A 68-year-old man presented with a 6-month
history of dyspnoea and orthopnoea. He also
reported a history of 5 kg weight loss and backache
during this period. Fever or cough was not
reported. He was a lifelong non-smoker, with no
known prior comorbid medical conditions.
On examination, he was in respiratory distress.
Vitals were: blood pressure 135/85 mm Hg, pulse
110/min, respiratory rate 30/min, temperature
37.4°C and oxygen saturation 94% on 6 L of supplemental oxygen. On chest examination, a non-tender,
10×12 cm soft tissue mass was palpable on the

Figure 1 Chest X-ray showing right-sided effusion with
mediastinal shifting. Lytic lesion visible on clavicles.
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Figure 2 CT scan chest mediastinal window showing a mass causing
erosion of right rib with underlying effusion.
plasmocytoma (ﬁgure 3A, B). Bone marrow examination
revealed aggregates of malignant CD138 positive plasma cells.
Skeletal survey displayed numerous lytic lesions scattered
throughout the body, including the skull, mandibles, spine,
scapula, radius, ulna and clavicles. Other test results included β2
macroglobulin levels of 19 087 ng/mL, κ light chain of 86 g/dL,
serum IgG of 46.17 g/L and a total protein of 10.7 g/dL (all signiﬁcantly elevated) supporting the diagnosis of MM with MPE.

Figure 4

Chest X-ray at the time of discharge.

DIFFERENTIAL DIAGNOSIS
1.
2.
3.
4.
5.

Pleural/pulmonary tuberculosis
Malignant pleural effusion
Fungal infection—(eg, actinomycosis)
Amyloidosis
Effusion due to renal failure

TREATMENT
The patient was started on dexamethasone, lenalidomide and
bortezomib for MM.

OUTCOME AND FOLLOW-UP
Initially, the patient underwent multiple thoracenteses due to
recurrent symptomatic MPE, followed by insertion of a pleural
catheter for drainage. With time, in response to the chemotherapy, there was signiﬁcant improvement in renal function (creatinine decreased from 4.4 to 1.9 mg/dL), reduction in the size of
the lung mass and complete resolution of the pleural effusion
(ﬁgure 4). The pleural catheter was hence removed. The
patient’s health improved steadily with resumption of daily physical activities. He was maintaining oxygen saturation on room
air at the time of discharge and continues to do well, a year after
diagnosis, when seen for routine follow-up as an outpatient.

DISCUSSION

Figure 3 (A) High-power view of sheets of atypical plasmacytoid
cells. (H&E stain, ×400 magniﬁcation). (B) Immunohistochemical
expression for (a) Mum-1, (b) CD138 and (c) CD56.
2

Pleural effusions are uncommon in MM. The vast majority of
pleural effusions in patients with myeloma are due to nonmyelomatous causes; these include pneumonia, cardiomyopathy,
nephrotic syndrome, renal failure, pulmonary embolism, secondary
neoplasms and amyloidosis. Pleural effusions that occur due to
involvement of the pleura by the malignant plasma cells (either
because of direct pleural invasion, or from extension of bony lesions
or from a lung mass/plasmacytoma), are termed as MPE. MPEs are
mainly seen with IgA subtype of myeloma cases (∼80% of MPEs
occur in IgA MM) compared to other subtypes.3 They mostly occur
on the left side of the chest1 4 and in general, present late in the
course of the disease.5 MPEs are diagnosed when malignant plasma
cells are seen on pleural ﬂuid cytology or pleural biopsy or there is
presence of M protein on pleural ﬂuid electrophoresis.
Treatment is aimed at the underlying cause of the effusion in
non-myelomatous effusions. For MPEs, no standardised therapy
exists, probably due to the infrequent number of cases.
Generally, systemic chemotherapy aimed at MM, in conjunction
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with chest tube drainage or pleurodesis for palliation, is used.
Prognosis is poor, with a median survival of 4 months.6–8
The case reported above is unusual in a few ways. MPE, along
with thoracic plasmacytoma (extramedullary plasmacytoma, like
MPE is also rare and only occur in 4–6% of MM cases), was the
initial presentation, which occurred in the right hemithorax and
the myeloma was of the IgG subtype. The patient had an excellent response to chemotherapy (including bortezomib, a newer
agent with proteasome inhibition properties and with promising
results in a few case reports of MPEs),5 so that his chest tube was
removed without pleurodesis, with no recurrence of the effusion.
The patient is well with signiﬁcant improvement of his mass and
renal failure, 1 year after the diagnosis of myeloma.
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▸ Pleural effusion, though rare, can be a presenting feature in
multiple myeloma (MM).
▸ MM should be considered as a possible diagnosis in a
patient with pleural effusion, backache and renal failure,
especially when the effusion has high protein content.
▸ Treatment of effusion in myeloma depends on the
underlying aetiology.
▸ Prognosis is usually poor.
▸ Bortezomib therapy may be useful in myelomatous pleural
effusion.
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